drugset / Trial / NCT02121990
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 1
Completed
17 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.
Timeline
- Start
- 2014-04-21
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 50 mg | Oral |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Other |
| Background | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |